Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Earnings for Soligenix, Inc. (SNGX)
Earnings in 2023 (TTM): $-7,908,533
According to Soligenix, Inc.'s latest financial reports the company's current earnings (TTM) are $-7,908,533. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Soligenix, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-7,908,533 | $-6,140,730 |
| 2022 | $-14,953,274 | $-13,798,339 |
| 2021 | $-13,415,715 | $-12,550,973 |
| 2020 | $-18,525,415 | $-17,688,522 |
| 2019 | $-9,966,268 | $-9,355,592 |
| 2018 | $-8,899,975 | $-8,899,975 |
| 2017 | $-7,563,893 | $-7,147,083 |
| 2016 | $-3,775,526 | $-3,245,383 |
| 2015 | $-8,320,163 | $-7,831,230 |
| 2014 | $-7,323,844 | $-6,706,972 |
| 2013 | $-10,809,352 | $-10,058,996 |
| 2012 | $-4,684,466 | $-4,163,007 |
| 2011 | $-2,952,751 | $-2,378,594 |
| 2010 | $-7,632,389 | $-7,386,579 |
| 2009 | $-6,053,695 | $-6,034,453 |
| 2008 | $ | $-3,422,027 |
| 2007 | $-6,328,470 | $-6,164,643 |
| 2006 | $-9,015,848 | $-8,163,346 |
| 2005 | $ | $-4,720,260 |
| 2004 | $-5,916,591 | $-5,871,574 |
| 2003 | $-5,288,531 | $-5,288,531 |
| 2002 | $-14,631,175 | $-4,966,081 |
| 2001 | $-14,631,175 | $-14,631,175 |
| 2000 | $-5,490,877 | $-4,795,693 |
| 1999 | $-7,937,746 | $-7,501,019 |
| 1998 | $-21,600,000 | $-21,800,000 |
| 1997 | $-3,000,000 | $-3,200,000 |
| 1995 | $-1,187,985 | $-1,187,985 |